Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC–MS/MS
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Pharmaceutical and Biomedical Analysis"
DOI: 10.1016/j.jpba.2017.04.053
Abstract: HighlightsPrecise, accurate and sensitive method to quantify two multikinase inhibitors and their 3 active metabolites simultaneously.Using confirmation/quantification ion ratios criteria to improve specificity.Dynamic range of the concentrations carrying out some pharmacokinetics studies. Abstract A new… read more here.
Keywords: simultaneous analysis; human plasma; regorafenib sorafenib; formic acid ... See more keywords
Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells.
Sign Up to like & getrecommendations! Published in 2018 at "Toxicology"
DOI: 10.1016/j.tox.2018.01.005
Abstract: Previous studies have shown that certain kinase inhibitors are mitochondrial toxicants. In the current investigation, we determined the mechanisms of mitochondrial impairment by the kinase inhibitors ponatinib, regorafenib, and sorafenib in more detail. In HepG2… read more here.
Keywords: kinase inhibitors; inhibitors ponatinib; regorafenib sorafenib; kinase ... See more keywords
Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.22334
Abstract: The purpose of this study was to investigate the antitumor activity of regorafenib and sorafenib in preclinical models of HCC and to assess their mechanism of action by associated changes in protein expression in a… read more here.
Keywords: regorafenib sorafenib; sorafenib preclinical; versus; preclinical models ... See more keywords